Helicobacter Pylori Eradication in Functional Dyspepsia

Summary

This study is designed to study benefit of eradicating Helicobacter Pylori in patients with functional dyspepsia as compared to symptomatic treatment only. Helicobacter pylori positive patients with Functional Dyspepsia will be divided into two study groups, one will receive Helicobacter pylori eradication therapy and other will receive symptomatic treatment. Symptom relief based on Likert scale will be compared in both groups.

Timeline

Start

2017-09-01

Primary completion

2019-05-31

Completion

2019-05-31

Outcome

Missed primary endpoint

paper Thirty-two patients in group 1 and 31 in group 2 had treatment success (31.7% vs. 30.7%, p=1.000). PMID 34708338 ↗

paper CONCLUSIONS: H. pylori eradication therapy does not provide additional benefit in symptom relief in patients with FD as compared with SMT. PMID 34708338 ↗

Publications

• Padole P, Ranjan P, Sachdeva M, Kumar M. Role of Helicobacter pylori eradication in patients with functional dyspepsia. Indian J Gastroenterol. 2021 Oct;40(5):492-501. doi: 10.1007/s12664-021-01195-3. Epub 2021 Oct 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amoxicillin	Other / unclassified	1000 mg	—
Subject	Clarithromycin	Small molecule	500 mg	—
Comparator	Acotiamide	Small molecule	100 mg	—
Comparator	Itopride	Small molecule	50 mg	—
Comparator	Levosulpiride	Small molecule	25 mg	—
Background	Pantoprazole	Other / unclassified	40 mg	—

Indications